Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Raised by Northern Trust Corp

Northern Trust Corp raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,827,771 shares of the biopharmaceutical company's stock after purchasing an additional 145,617 shares during the quarter. Northern Trust Corp owned 1.44% of Halozyme Therapeutics worth $87,386,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust lifted its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now owns 33,108 shares in the company, valued at $2,120,567.40. The trade was a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,697 shares of company stock valued at $1,276,552 over the last 90 days. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on HALO shares. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday. HC Wainwright restated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Finally, Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $63.78.

Halozyme Therapeutics Stock Down 2.8 %

Shares of HALO stock traded down $1.87 during trading hours on Friday, hitting $65.86. 2,501,725 shares of the company were exchanged, compared to its average volume of 1,499,455. The stock has a market capitalization of $8.14 billion, a price-to-earnings ratio of 19.20, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The business's 50-day simple moving average is $61.45 and its two-hundred day simple moving average is $55.83. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter last year, the business posted $0.79 EPS. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.